ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Tumor Infiltrating Lymphocytes GT201

Also written as “GT201”, “Autologous tumor infiltrating lymphocyte injection(GT201)” and “GT201 injection”.

Its studies are mostly in Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageAutologous Tumor Infiltrating Lymphocytes GT201: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 6, 20239 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grit Biotechnologyits history only82 open or runningphase 2since Feb 6, 2023Jun 4, 2022Apr 30, 2027NCT06190275
Gritbio Medicineits history only11 open or runningphase 2since Jul 27, 2026Jul 27, 2026Jun 2030phase 2 · NCT07766317

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 4, 2022First study: phase 1 study in Solid TumorNew to Grit BiotechnologyGrit Biotechnology · NCT05430360 · 2 enrolled · China
  2. Feb 6, 2023Phase 2 study in Solid TumorGrit Biotechnology · NCT05729399 · 6 enrolled · China
  3. Oct 20, 2023Phase 2 study in Advanced Solid TumorsGrit Biotechnology · NCT06144671 · 78 planned · China
  4. Dec 19, 20232 no phase studiesGrit Biotechnology · NCT06190275, NCT06191900
  5. Jan 23, 2024No phase study in Carcinoma, Non-Small-Cell LungGrit Biotechnology · NCT06235242 · 2 enrolled · China
  6. Jul 19, 2024No phase study in Lung NeoplasmsGrit Biotechnology · NCT06519669 · 2 enrolled · China
  7. Feb 5, 2025Early phase 1 study in Adult Gynecological TumorsGrit Biotechnology · NCT06834542 · 1 enrolled · China
  8. Jul 27, 2026Gritbio Medicine’s first study: phase 2 study in Advanced Solid Tumors CancerNew to Gritbio MedicineGritbio Medicine · NCT07766317 · 63 planned

Ahead

  1. Apr 30, 2027Primary completion: no phase study in Squamous Cell Carcinoma of Head and NeckGrit Biotechnology · NCT06190275
  2. Dec 30, 2027Primary completion: phase 2 study in Advanced Solid TumorsGrit Biotechnology · NCT06144671
  3. Jun 2030Primary completion: phase 2 study in Advanced Solid Tumors CancerGritbio Medicine · NCT07766317

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07766317Advanced Solid Tumors Cancer2Not yet recruitingGritbio MedicineJun 203063
NCT06834542Adult Gynecological Tumors · ChinaEarly 1TerminatedGrit BiotechnologyDec 30, 20251
NCT06519669Lung Neoplasms · China–TerminatedGrit BiotechnologyDec 30, 20252
NCT06235242Carcinoma, Non-Small-Cell Lung · China–TerminatedGrit BiotechnologyDec 30, 20252
NCT06191900Adult · China–TerminatedGrit BiotechnologyDec 30, 20254
NCT06190275Squamous Cell Carcinoma of Head and Neck · China–RecruitingGrit BiotechnologyApr 30, 202732
NCT06144671Advanced Solid Tumors · China2RecruitingGrit BiotechnologyDec 30, 202778
NCT05729399Solid Tumor · China2TerminatedGrit BiotechnologyDec 30, 20256
NCT05430360Solid Tumor · China1TerminatedGrit BiotechnologyDec 30, 20252

How it is read

Names in the registry

  • “GT201”, 4 entries
  • “Autologous tumor infiltrating lymphocyte injection(GT201)”, 2 entries
  • “GT201 injection”, 1 entry
  • “GT201 injection in combination with teraplizumab injection”, 1 entry
  • “GT201 in combination with PD-1 inhibitors”, 1 entry

Codes read as this program: GT201.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.